Halpin, David M. G.
Criner, Gerard J.
Dransfield, Mark T.
Han, MeiLan K.
Hartley, Benjamin
Harvey, Catherine
Jones, C. Elaine
Kato, Motokazu
Lange, Peter
Lettis, Sally
Lomas, David A.
Martinez, Fernando J.
Martin, Neil
Singh, Dave
Wise, Robert
Zheng, Jinping
Lipson, David A.
Clinical trials referenced in this document:
Documents that mention this clinical trial
P248 Risk of exacerbation and pneumonia with single inhaler triple versus dual therapy in IMPACT
https://doi.org/10.1136/thorax-2018-212555.404
P250 Informing the pathway of COPD treatment (the IMPACT study): single inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with COPD – cost-effectiveness in the UK
https://doi.org/10.1136/thorax-2018-212555.406
P249 Informing the pathway of COPD treatment (the IMPACT study): single inhaler triple therapy (FF/UMEC/VI) versus dual bronchodilator therapy (UMEC/VI) in patients with COPD – cost-effectiveness in the UK
https://doi.org/10.1136/thorax-2018-212555.405
Triple Versus Dual Combination Therapy in Chronic Obstructive Pulmonary Disease in Asian Countries: Analysis of the IMPACT Trial
https://doi.org/10.1007/s41030-020-00136-3
Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study
https://doi.org/10.1007/s12325-020-01409-8
Estimating individual treatment effects on COPD exacerbations by causal machine learning on randomised controlled trials
https://doi.org/10.1136/thorax-2022-219382
Funding for this research was provided by:
GlaxoSmithKline
Article History
Received: 27 August 2020
Accepted: 15 October 2020
First Online: 17 November 2020